Skip to content
Subscriber Only

Glaxo’s Melanoma Cocktail Advances After Promising First Trial

GlaxoSmithKline Plc’s combination of two experimental drugs for advanced melanoma helped almost all patients in its first human study, leading it to launch the therapy directly into large trials needed for U.S. approval.

The pills target genetic variations that drive growth of melanoma, the deadliest skin cancer. Both drugs had been shown to help combat the disease in those with a mutation known as BRAF, found in about half of patients, though each carried side effects and had limited benefit when given separately.